Aspira Women's Health Inc. reported its financial results for the first quarter of 2025, revealing a revenue increase to approximately $2.28 million, up from $2.15 million in the same period of 2024, marking a 5.9% growth. The rise was primarily attributed to select price increases implemented during the quarter. The company also highlighted a 94% increase in sales per full-time equivalent salesperson compared to the first quarter of 2024, driven by strategic changes in market approach by the new executive team. Gross profit improved significantly, reaching approximately $1.6 million, a 28.5% increase from $1.2 million in the previous year. Gross margins increased to 68.5% from 56.4%, benefiting from a one-time reduction in accruals and enhanced profitability of the OvaWatch® product line. Operating expenses saw a notable reduction, declining to $4.8 million, a 19% decrease from $5.9 million in the same period of the prior year. This was primarily due to a $0.8 million decrease in selling expenses and a $0.4 million reduction in general and administrative expenses, partially offset by a $0.1 million increase in research and development expenses. The company reported a net loss of $1.853 million for the quarter, an improvement from the $4.629 million loss in the first quarter of 2024. The cash used in operations decreased to $3.1 million, representing a 30% reduction in operating cash burn from the previous year. In terms of business updates, Aspira emphasized its focus on executing an aggressive research and development timeline for ENDOInform™, with expectations to provide significant updates by the end of 2025. The company remains dedicated to advancing non-invasive diagnostic tools for gynecologic diseases, including ongoing developments in its ovarian cancer and endometriosis testing portfolios.